Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IK-175 + Nivolumab in Resistant HNSCC
NCT05472506Phase 1Withdrawn
- Sponsor
- ImageneBio
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of IK-175 in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by ImageneBio. Primary endpoints: Treatment Emergent Adverse Events at 18 months, Treatment Related Adverse Events at 18 months and 5 more. Planned start Mar 2023; status: withdrawn.
02
Drugs
IK-175
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05472506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472506.